Significance of the Kinetics of Immunotoxin Cytotoxicity

  • F. K. Jansen
  • H. E. Blythman
  • B. Bourrie
  • D. Carriere
  • P. Casellas
  • D. Dussossoy
  • O. Gros
  • J. C. Laurent
  • M. C. Liance
  • P. Poncelet
  • G. Richer
  • H. Vidal


Since 1980, immuno-A-toxins (I-A-Ts) which are conjugates between an antibody and the A-chain of a polypeptide toxin, e.g., diphtheria toxin or ricin, have been described by several laboratories as cytotoxic agents with high specificity for their target cells.1–15 However, there was great variation from high to low potency depending on the antigen-immunotoxin (IT) system used. The advantage of the I-A-Ts is their low non-specific toxicity in-vivo (LD/50 in mice 20mg/kg),16 which will allow their utilization in human patients in the near future.


Ammonium Chloride Human Bone Marrow Protein Synthesis Inhibition Diphtheria Toxin Autologous Bone Marrow Transplantation 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    D.G. Gilliland, Z. Steplewski, R.J. Collier, K.F. Mitchell, T.H. Chang and H. Koprowski, Antibody-directed cytotoxic agents: Use of monoclonal antibody to direct the action of toxic A chains to colorectal carcinoma cells, Biochem. J., 77:4539 (1980).Google Scholar
  2. 2.
    F.K. Jansen, H.E. Blythman, D. Carriere, P. Casellas, J. Diaz, P. Gros, J.R. Hennequin, F. Paolucci, B. Pau, P. Poncelet, G. Richer, S.L. Salhi, H. Vidal and G.A. Voisin, High specific cytotoxicity of antibody-toxin hybrid molecules (immunotoxins) for target cells, Immunol. Lett. 2:97 (1980).CrossRefGoogle Scholar
  3. 3.
    K.A. Krolick, C. Villemez, P. Isakson, J.W. Uhr and E.S. Vitetta, Selctive killing of normal or neoplastic B cells by antibodies coupled to the A chain of ricin, Proc. Natl. Acad. Sci USA, 77:5419 (1980).PubMedCrossRefGoogle Scholar
  4. 4.
    Y. Masuho and T. Hara, Target-cell cytotoxicity of a hybrid of Fab’ of immunoglobulin and A chain of ricin, Gann, 71:759 (1980).PubMedGoogle Scholar
  5. 5.
    H. Miyazaki, M. Beppu, T. Terao and T. Osawa, Preparation of antibody (IgG)-ricin A chain conjugate and its biologic activity, Gann, 71:766 (1980).PubMedGoogle Scholar
  6. 6.
    V. Raso and T. Griffin, Specific cytotoxicity of a human immunoglobulin-directed Fab’ ricin A-chain conjugate, J. Immunol. 125:2610 (1980).PubMedGoogle Scholar
  7. 7.
    H.E. Blythman, P. Casellas, O. Gros, P. Gros, F.K. Jansen, F. Paolucci, B. Pau and H. Vidal, Immunotoxins: Hybrid molecules of monoclonal antibodies and a toxin subunit specifically kill tumour cells, Nature. 290:145 (1981).PubMedCrossRefGoogle Scholar
  8. 8.
    L.L. Houston and R.C. Nowinski, Cell-specific cytotoxicity expressed by a conjugate of ricin and murine monoclonal antibody directed against Thy 1.1 antigen, Cancer Res. 41:3913(1981).PubMedGoogle Scholar
  9. 9.
    K.A. Krolick, D. Yuan and E.S. Vitetta, Specific killing of a human breast carcinoma cell line by a monoclonal antibody coupled to the A chain of ricin, Cancer Immunol. Immunother, 12:39 (1981).CrossRefGoogle Scholar
  10. 10.
    T.N. Oeltmann and J.T. Forbes, Inhibition of mouse spleen cell function by diphtheria toxin fragment A coupled to anti-mouse Thy 1.2 and by ricin A-chain coupled to anti mouse IgM. Arch. Biochem. Biophys. 209:362 (1981).PubMedCrossRefGoogle Scholar
  11. 11.
    I.S. Trowbridge and D.L. Domingo, Anti-transferrin receptor monoclonal antibody and toxin-antibody conjugates affect growth of human tumour cells, Nature, 294 (1981).Google Scholar
  12. 12.
    T.W. Griffin, L.R. Haynes and J.A. Demartino, Selective cytotoxicity of a ricin A-chain-anti-carcinoembryonic antigen antibody conjugate for a human colon adenocarcinoma cell line, JNCI, 69:799 (1982).PubMedGoogle Scholar
  13. 13.
    V. Raso, J. Ritz, M. Basala and S.F. Schlossman, Monoclonal antibody-ricin A-chain conjugate selectively cytotoxic for cells bearing the common acute lymphoblastic leukemia antigen, Cancer Research, 42:457 (1982).PubMedGoogle Scholar
  14. 14.
    M.I. Bernhard, K.A. Foon, T.N. Oeltmann, M.E. Key, K.M. Hwang, G.C. Clarke, W.L. Christensen, L.C. Hoyer, M.G. Hanna, Jr. and R.K. Oldham, Guinea pig line 10 hepatocarcinoma model: Characterization of monoclonal antibody and in-vivo effect of unconjugated antibody and antibody conjugated to diphtheria toxin A chain, Cancer Res. 43:4420 (1983).PubMedGoogle Scholar
  15. 15.
    G. Moller, ed., “Antibody Carriers of Drugs and Toxins in Tumor Therapy”, Immunological Reviews vol. 62, Munksgaard, Copenhagen (1982).Google Scholar
  16. 16.
    F.K. Jansen, H.E. Blythman, D. Carriere, P. Casellas, O. Gros, P. Gros, J.C. Laurent, F. Paolucci, B. Pau, P. Poncelet, G. Richer, H. Vidal and G.A. Voisin, Immunotoxins: Hybrid molecules combining high specificity and potent cytotoxicity, in: “Antibody Carriers of Drugs and Toxins in Tumor Therapy”, Immunological Reviews, G. Moller, ed., vol.62, Munksgaard, Copenhagen (1982).Google Scholar
  17. 17.
    F.L. Moolten and S.R. Cooperband, Selective destruction of target cells by diphtheria toxin conjugated to antibody directed against antigens on the cells, Science, 169:68 (1970).PubMedCrossRefGoogle Scholar
  18. 18.
    P.E. Thorpe, W.C.J. Ross, A.J. Cumber, C.A. Hinson, D.C. Edwards, A.J.S. Davies, Toxicity of diphtheria toxin for lymphoblasted cells is increased by conjugation to antilymphocytic globulin, Nature, 271:752 (1978).PubMedCrossRefGoogle Scholar
  19. 19.
    J.R. Youle and D.M. Neville, Jr., Anti-Thy 1.2 monoclonal antibody linked to ricin is a potent cell-type-specific toxin, Proc. Natl. Acad. Sci. USA, 77:5483 (1980).PubMedCrossRefGoogle Scholar
  20. 20.
    F.K. Jansen, H. Blythman, D. Carriere, P. Casellas, P. Gros, F. Paolucci, B. Pau, P. Poncelet, G. Richer and H. Vidal, Replacement of the B chain of ricin with specific conventional or monoclonal antibodies, in: “Receptor-mediated binding and internalization of toxins and hormones”, J.L. Middlebrook and L.D. Kohn, eds., Academic Press, New York (1981).Google Scholar
  21. 21.
    R.J. Youle and D.M. Neville, Kinetics of protein synthesis inactivation by ricin-anti-Thy 1.1 monoclonal antibody hybrids: Role of the ricin B subunit demonstrated by reconstitution, J. Biol. Chem. 257:1598 (1982).PubMedGoogle Scholar
  22. 22.
    P. Casellas, J.P. Brown, O. Gros, P. Gros, I Hellstrom, F.K. Jansen, P. Poncelet, R. Roncucci, H. Vidal and K.E. Hellstrom, Human melanoma cells can be killed in-vitro by an immunotoxin specific for melanoma-associated antigen p97, Int. J. Cancer, 30:437 (1982).PubMedCrossRefGoogle Scholar
  23. 23.
    P. Casellas, H.E. Blythman, P. Gros, G. Richer and F.K. Jansen, High efficiency of immunotoxin potentiated by lysosomotropic amines to specifically kill tumor cells in: “Rotides of the Biological Fluids”, H. Peeters, ed., Pergamon Press, Oxford (1982).Google Scholar
  24. 24.
    S. Olnes and A. Pihl, Toxic lectins and related proteins, in: “The molecular actions of toxins and viruses”, Ph. Cohen and S. van Heyningen, eds., Elsevier/North Holland, Amsterdam (1980).Google Scholar
  25. 25.
    P. Casellas and B. Bourrie, in preparation.Google Scholar
  26. 26.
    R.J. Youle, G.J. Murray and D.M. Neville, Jr., Studies on the galactose-binding site of ricin and the hybrid toxin man6P-ricin, Cell, 23:551 (1981).PubMedCrossRefGoogle Scholar
  27. 27.
    P. Thorpe, A. Brown, B. Foxwell, C. Myers, W. Ross, A. Cumber and T. Forrester, Blockade of the galactose-binding site of ricin by its linkage to antibody, in: “Monoclonal Antibodies and Cancer”, Proceedings of the 4th Armand Hammer Cancer Conference, La Jolla, R.E. Langman, I.S. Trowbridge and R. Dulbecco, eds., Academic Press, New York (1983).Google Scholar
  28. 28.
    E.S. Vitetta, W. Cushley and J.W. Uhr, Synergy of ricin A chain-containing immunotoxins and ricin B chain-containing immunotoxins in in-vitro killing of neoplastic human B cells, Proc. Natl. Acad. Sci. USA, 80:6332 (1983).PubMedCrossRefGoogle Scholar
  29. 29.
    D. Carriere, submitted.Google Scholar
  30. 30.
    P. Casellas, submitted.Google Scholar
  31. 31.
    P. Casellas, in preparation.Google Scholar
  32. 32.
    O. Gros, P. Casellas, J. Leonard, I. Royston and F.K. Jansen, Immunotoxins with whole ricin or A chain: comparison of efficiency and specificity, in: “Bacterial Protein Toxins”, Proceedings of the Scillac Workshop Conference, J.E. Alouf, F. Fehrenbach, H. Freer and J. Jeljaszewicz, eds., Academic Press, London (1983).Google Scholar
  33. 33.
    P. Poncelet, in preparation.Google Scholar
  34. 34.
    P. Casellas, D. Carriere, O. Gros, J.C. Laurent, P. Poncelet and F.K. Jansen, Properties of antibody-ricin A-chain conjugates (immunotoxins) in specific cell killing, in: “Bacterial Protein Toxins”, Proceedings of the Scillac Workshop Conference, J.E. Alouf, F. Fehrenbach, H Freer and J. Jeljaszewicz, eds., Academic Press, London (1983).Google Scholar
  35. 35.
    H. Blythman, in preparation.Google Scholar
  36. 36.
    M.I. Bernhard, K.M. Hwang, K.A. Foon, A.M. Keenan, R.M. Kessler, J.M. Frincke, D.J. Tallam, M.G. Hanna, Jr., Leona Peters and R.K. Oldham, Localization of 111In-and 125I-labeled monoclonal antibody in guinea pigs bearing line 10 hepatocarcinoma tumors, Cancer Res., 43:4429 (1983).PubMedGoogle Scholar
  37. 37.
    K.A. Krolick, J.W. Uhr, S. Slavin and E.S. Vitetta, In-vivo therapy of a murine B cell tumor (BCL1) using antibody-ricin A-chain immunotoxins, J. Exp. Med. 155:1797 (1982).PubMedCrossRefGoogle Scholar
  38. 38.
    M. Seto, N. Umemoto, M. Saito, Y. Masuho, T. Hara and T. Takahashi, Monoclonal Anti-MM46 antibody ricin A chain conjugate: In-vitro and in-vivo antitumor activity, Cancer Res. 42:5209 (1982).PubMedGoogle Scholar
  39. 39.
    H. Kaiser, R. Levy, C. Browall, C.I. Civin, D.J. Fuller, S.H. Hsu, B.G. Leventhal, R.A. Miller, E.S. Milvenan, G.W. Santos and M.D. Wharam, Autologous bone marrow transplantation in T-cell malignancies: A case report involving in-vitro treatment of marrow with a pan-T-cell monoclonal antibody, J. Biol. Resp. Modif., 1:233 (1983).Google Scholar
  40. 40.
    D.A. Vallera, R.J. Youle, D.M. Neville, Jr., and J.H. Kersey, Bone marrow transplantation across major histocompatibility barriers. Protection of mice from lethal graft-versus-host disease by pretreatment of donor cells with monoclonal anti-Thy 1.2 coupled to the toxin ricin, J. Exp. Med. 155:949 (1982).PubMedCrossRefGoogle Scholar
  41. 41.
    R.C Bast, J. Ritz, J.M. Lipton, M. Feeney, S.E. Sallan, D.G. Nathan and S.F. Schlossman, Elimination of leukemic cells from human bone marrow using monoclonal antibody and complement, Cancer Res., 43:1389 (1983).PubMedGoogle Scholar
  42. 42.
    K.A. Krolick, J.W. Uhr and E.S. Vitetta, Selective killing of leukaemia cells by antibody-toxin conjugates: implications for autologous bone marrow transplantation, Nature. 295:604 (1982).PubMedCrossRefGoogle Scholar
  43. 43.
    M. Muirhead, P.J. Martin, B. Torok-Storb, J.W. Uhr and E.S. Vitetta, Use of an antibody-ricin A-chain conjugate to delete neoplastic B cells from human bone marrow, Blood. 62:322 (1983).Google Scholar
  44. 44.
    P.E. Thorpe, D.W. Mason, A.N.F. Brown, S.J. Simmonds, W.C.J. Ross, A.J. Cumber and J.A. Forrester, Selective killing of malignant cells in a leukemic rat bone marrow using an antibody-ricin conjugate, Nature. 297:594 (1982).PubMedCrossRefGoogle Scholar
  45. 45.
    N.C Gorin, L. Douay, F.K. Jansen, G.A. Voisin, C. Baillou, A. Najman and G. Duhamel, Etude de l’immunotoxine T101: Absence de toxicite envers les proge-niteurs hematopoietique CFUc et BFUe: application possible a l’auto-greffe de moelle osseuse, Hematologie 25:204 (1983).Google Scholar
  46. 46.
    N.C. Gorin, L. Douay, F.K. Jansen, G.A. Voisin, C. Baillou, A. Nahman, and G. Duhamel, Study of immunotoxin T101: Absence of cytotoxicity against hemopoietic progenitor stem cells. Application to in-vitro therapy prior to autologous bone marrow transplantation, in: “Minimal Residual Disease In Acute Leukemia”, B. Lowenberg, A. Hagenbeeck and M. Nijhoff, eds., The Hague Netherlands Publishers (1984).Google Scholar
  47. 47.
    R.C. Bast, Jr., P. Maver, C Lipton, J. Rit, J. Nadler, L. Sallan, S. Nathan, D.G. and S.F. Schlossman, Elimination of malignant clonogenic cells from human bone marrow using multiple monoclonal antibodies and complement. Proceedings of the Annual Meeting of the American Association for Cancer Research, Vol. 24. (1983).Google Scholar
  48. 48.
    D. Vallera, R.C. Ash, E.D. Zanjani, J.M. Kersey, T.W. Lebien, P.C.L. Beverley, D.M. Neville and R.J. Youle, Anti-T-cell reagents for human bone marrow transplantation: Ricin linked to three monoclonal antibodies, Science, in press.Google Scholar

Copyright information

© Plenum Press, New York 1984

Authors and Affiliations

  • F. K. Jansen
    • 1
  • H. E. Blythman
    • 1
  • B. Bourrie
    • 1
  • D. Carriere
    • 1
  • P. Casellas
    • 1
  • D. Dussossoy
    • 1
  • O. Gros
    • 1
  • J. C. Laurent
    • 1
  • M. C. Liance
    • 1
  • P. Poncelet
    • 1
  • G. Richer
    • 1
  • H. Vidal
    • 1
  1. 1.Section ImmunologieCentre de Recherches Clin-MidyMontpellierFrance

Personalised recommendations